Cancer options, sourced carefully
Understand the options before the next oncology visit.
MatchMedi helps families read source-linked treatment categories, prepare sharper doctor questions, search trials, and learn from verified patient and caregiver experiences. It is an options navigator, not a treatment recommender.
Coverage map
Melanoma is deep. Other cancers are careful overviews.
The site now supports more cancer entry points, but it labels depth honestly so broader coverage does not look like complete treatment coverage.
Deep coverage
Melanoma
The first deep MatchMedi area, with mutation pages, treatment records, trial-search support, and cohort forum threads.
Source-backed overview
Lung cancer
A high-priority next cancer area because treatment conversations often depend on subtype, stage, biomarkers, and clinical trial timing.
Source-backed overview
Breast cancer
A planned source-backed overview area for organizing subtype, receptor status, stage, and treatment-category questions.
Source-backed overview
Colorectal cancer
A planned overview for organizing colon/rectal cancer source links, biomarker questions, stage, surgery, systemic therapy, and trials.
Source-backed overview
Leukemia
A source-backed leukemia entry point for organizing the exact subtype, acute versus chronic pattern, marrow/blood testing, molecular reports, transplant questions, and trial timing.
Source-backed overview
Leukemia / lymphoma
A legacy paired blood-cancer entry point. Leukemia now has its own source-backed page; lymphoma remains planned for a separate module.
Source-backed overview
Pediatric solid tumors
A planned pediatric entry point that should be built with extra caution, pediatric sources, and family-support language.
Evidence labels
Every option needs a clear source label.
Known
Source-backed
Approval, trial, mutation, and treatment-category statements are tied to visible sources.
Unclear
Kept separate
Similar drugs or nearby trial ideas are not merged into proof for a different combination.
Experience
Not evidence
Cohort stories are useful for questions, but they do not become treatment proof.
Melanoma first
NRAS is where the project starts going deep.
Melanoma is the first full library because the founding story is personal and the decision landscape is genuinely difficult: immunotherapy, surgery, mutation testing, trials, country-specific access, and the painful question of what comes after PD-1 / PD-L1 failure.
Read tunlametinib / HL-085 pageCohort stories are not advice
Patient and parent experiences can show what questions people wish they had asked. They do not show what another person should take, stop, combine, or dose.
Start a verified threadAfter PD-1 / PD-L1 failure
A clearer map for NRAS melanoma conversations.
Families often hear several names at once: PD-1 drugs, MEK inhibitors, TIL therapy, China-specific options, and trial drugs that sound similar but are not the same. MatchMedi now separates those buckets so the next oncology visit can be more organized.
Tunlametinib / HL-085
China-specific MEK inhibitor context after PD-1/PD-L1 failure.
Lifileucel / TIL therapy
FDA accelerated-approval context after prior PD-1 therapy.
Lookalike NRAS trials
Belvarafenib/cobimetinib/nivolumab is tracked separately from tunlametinib.
Visit pathway
Gather prior treatments, mutation report, scans, and trial-search constraints.
Cohort stories
Read lived experience separately from evidence and trial records.
Trial search terms
Search registry text without treating a match as proof that a study fits.
Trust strip